Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Dose-escalation and Dose-finding, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KN510, KN713 as Combination Therapy in Patients With Advanced Solid Tumors

NCT06012708 is registered in ClinicalTrials.gov with New Cancer Cure-Bio Co.,Ltd. as lead sponsor.

NCT NCT06012708
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06012708 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Dose-escalation and Dose-finding, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KN510, KN713 as Combination Therapy in Patients With Advanced Solid Tumors
Lead sponsor
New Cancer Cure-Bio Co.,Ltd.
Phase
Phase 1
Overall status
Completed
Start date
September 11, 2023
Completion date
December 16, 2024
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors